Managing Metastatic Prostate Cancer in Your Urological Oncology Practice
Enzalutamide in metastatic castration resistant prostate cancer
Book sections
Shevach, J; Marcellino, BK; Oh, WK; Tsao, CK
January 1, 2016
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Citation
APA
Chicago
ICMJE
MLA
NLM
Shevach, J., Marcellino, B. K., Oh, W. K., & Tsao, C. K. (2016). Enzalutamide in metastatic castration resistant prostate cancer. In Managing Metastatic Prostate Cancer in Your Urological Oncology Practice (pp. 157–169). https://doi.org/10.1007/978-3-319-31341-2_10
Shevach, J., B. K. Marcellino, W. K. Oh, and C. K. Tsao. “Enzalutamide in metastatic castration resistant prostate cancer.” In Managing Metastatic Prostate Cancer in Your Urological Oncology Practice, 157–69, 2016. https://doi.org/10.1007/978-3-319-31341-2_10.
Shevach J, Marcellino BK, Oh WK, Tsao CK. Enzalutamide in metastatic castration resistant prostate cancer. In: Managing Metastatic Prostate Cancer in Your Urological Oncology Practice. 2016. p. 157–69.
Shevach, J., et al. “Enzalutamide in metastatic castration resistant prostate cancer.” Managing Metastatic Prostate Cancer in Your Urological Oncology Practice, 2016, pp. 157–69. Scopus, doi:10.1007/978-3-319-31341-2_10.
Shevach J, Marcellino BK, Oh WK, Tsao CK. Enzalutamide in metastatic castration resistant prostate cancer. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice. 2016. p. 157–169.